NextCure  Inc (NXTC)

Currency in USD
6.020
-0.560(-8.51%)
Real-time Data·
Earnings results expected in 15 days
NXTC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.4006.250
52 wk Range
1.55015.740
Key Statistics
Prev. Close
6.58
Open
5.54
Day's Range
5.4-6.25
52 wk Range
1.55-15.74
Volume
3.28M
Average Volume (3m)
1.87M
1-Year Change
27.584%
Book Value / Share
7.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NXTC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.000
Upside
+232.23%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

NextCure  Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.000
(+232.23% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy20.00+223.62%-MaintainJul 15, 2026
Lucid Capital Markets
Buy25.00+304.53%-New CoverageMay 11, 2026
Ladenburg Thalmann
Buy18.00+191.26%-UpgradeNov 07, 2025
H.C. Wainwright
Buy20.00+223.62%3.00MaintainAug 08, 2025

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-1.87 / -0.45
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NXTC Income Statement

Compare NXTC to Peers and Sector

Metrics to compare
NXTC
Peers
Sector
Relationship
P/E Ratio
−0.4x−3.5x−0.4x
PEG Ratio
−0.02−0.020.00
Price/Book
0.9x1.8x2.6x
Price / LTM Sales
-29.2x3.0x
Upside (Analyst Target)
204.0%164.7%53.2%
Fair Value Upside
Unlock3.7%9.5%Unlock

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
232.92K6.45%507.77K
Other Institutional Investors
2.71M75.05%5.91M
Public Companies & Retail Investors
668.16K18.50%1.46M
Total
3.61M100.00%7.87M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Simcere Pharmaceutical Group Limited9.38%338,636738
Squadron Capital Management Llc7.34%265,000578

People Also Watch

3.675
MX
-5.53%
4.22
CRMT
-1.40%
1.310
AUUD
+1.55%
3.2399
HTCO
+5.19%
13.4200
AKTX
0.00%

FAQ

What Is the NextCure (NXTC) Stock Price Today?

The NextCure stock price today is 6.020 USD.

What Stock Exchange Does NextCure Trade On?

NextCure is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for NextCure?

The stock symbol for NextCure is "NXTC."

What Is the NextCure (NXTC) Afterhours Price Today? (Afterhours variable test: 5.420) Current Date: Jul 15, 2026

After hours price: 5.420. After hours price change (units): -1.160. Price change percentage: -17.630%

What Is the NextCure Market Cap?

As of today, NextCure market cap is 21.560M USD.

What Is NextCure's Earnings Per Share (TTM)?

The NextCure EPS (TTM) is -15.317.

When Is the Next NextCure Earnings Date?

NextCure will release its next earnings report on Jul 30, 2026.

From a Technical Analysis Perspective, Is NXTC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has NextCure Stock Split?

NextCure has split 1 times.

How Many Employees Does NextCure Have?

NextCure has 40 employees.

What is the current trading status of NextCure (NXTC)?

As of Jul 15, 2026, NextCure (NXTC) is trading at a price of 6.020 USD, with a previous close of 6.580 USD. The stock has fluctuated within a day range of 5.400 USD to 6.250 USD, while its 52-week range spans from 1.550 USD to 15.740 USD.

What Is NextCure (NXTC) Price Target According to Analysts?

The average 12-month price target for NextCure is 20.000 USD, with a high estimate of 25 USD and a low estimate of 15 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +232.23% Upside potential.

What Is the NXTC Premarket Price?

NXTC's last pre-market stock price is 5.520 USD. The pre-market share volume is 977,550.000, and the stock has decreased by -1.060, or -16.110%.

What Is the NXTC After Hours Price?

NXTC's last after hours stock price is 5.420 USD, the stock has decreased by -1.160, or -17.630%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.